Patient-Derived Tumor Organoids: A Promising Tool for Personalized Cancer Therapy

Abstract

Patient Derived Organoids (PDOs) are described as miniature, three dimensional (3D) cell cultures prepared from patient’s cancer cell to compare therapeutic responses in the laboratory and clinical settings. Personalized cancer medicine is a novel therapeutic strategy to identify a right treatment for the right patient in accordance with tumor’s genetic signature. Tumor Organoid models have innumerable benefits over pre-existing models which makes them a tremendous candidate in personalized cancer therapy as they mimic the physiology of the original tumor. Recently several studies have shown the value of these “tumor in-dish” approaches in personalized cancer medicine for preclinical drug screening and prediction of patient treatment outcome. The objective of this “Journal of Carcinogenesis and Mutagenesis” research topic is to advance our current understanding about PDOs as an attractive in vitro model system for studying tumor evolution and response to drugs and treatments.